Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 7, 2012

Primary Completion Date

July 1, 2018

Study Completion Date

January 16, 2019

Conditions
Prostatic Neoplasms
Interventions
DRUG

Cabozantinib

Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.

DRUG

Docetaxel

75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.

DRUG

Prednisone

5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01683994 - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter